Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

  3. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. ELMO 3 expression in metastasizing malignant gliomas

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskningpeer review

  • Steinbjørn Hansen
  • Birthe Krogh Rasmussen
  • René Johannes Laursen
  • Michael Kosteljanetz
  • Henrik Schultz
  • Bente Mertz Nørgård
  • Rikke Guldberg
  • Kim Oren Gradel
Vis graf over relationer

BACKGROUND: As many glioblastoma patients are in a poor condition they are unable to undergo the full treatment documented in clinical trials. We aimed to examine the survival and its relationship to clinical characteristics and treatment in a nationwide population of glioblastoma patients in Denmark.

METHODS: We included prospectively recorded clinical data from 1364 adult patients with histologically verified glioblastoma from the Danish Neuro-Oncology Registry, 2009-2014.

RESULTS: The age standardized incidence rate was 6.3/100,000 person-years for males and 3.9 for females and the median age was 66 years. The median overall survival was 11.2 months. There was an independently significant prognostic effect of age, performance status, cognitive symptoms, tumor diameter, multifocality, crossing midline, and contrast enhancement. For partial and total resection compared to biopsy only, the adjusted risk of dying was reduced by 43% (HR [CI] 0.57 [0.48-0.68]) and 51% (0.49 [0.40-0.60]), respectively. For patients receiving a partial and full radiochemotherapy regimen compared to no postsurgical treatment, the risk reduction was 56% (HR [CI] 0.44 [0.37-0.53]) and 70% (0.30 [0.25-0.35]), respectively. The full radiochemotherapy regimen was only allocated to 50% of the patients, 29% among the oldest (70+ years) and 60% among the younger (18-69 years).

CONCLUSIONS: Glioblastoma patients had a poor overall survival but with several specific independent prognostic factors. Extensive cancer treatment was associated with an increasing survival in all age groups, but only half of the patients were sufficiently fit for a full regimen of postoperative combined radiochemotherapy.

OriginalsprogEngelsk
TidsskriftJournal of Neuro-Oncology
Vol/bind139
Udgave nummer2
Sider (fra-til)479-489
Antal sider11
ISSN0167-594X
DOI
StatusUdgivet - 2018

ID: 58154426